Trial · NCT00523341
Registered outcomes48
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
21 to 40 of 48
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Secondary | Bone Histomorphometry: Trabecular Number | Month 24 and month 84 | Bone biopsy samples were prepared according to standard procedures for bone histomorphometry. Trabecular number is the number of trabeculae present per lineal mm and is calculated as trabecular bone volume/trabecular thickness. Trabecular number is a measure of trabecular connectivity and decreases with bone loss. |
| Secondary | Bone Histomorphometry: Trabecular Separation | Month 24 and month 84 | Bone biopsy samples were prepared according to standard procedures for bone histomorphometry. Trabecular separation is the mean distance between trabeculae (measured by integrated computer graphics). Trabecular separation increases with trabecular bone loss. |
| Secondary | Bone Histomorphometry: Trabecular Thickness | Month 24 and month 84 | Bone biopsy samples were prepared according to standard procedures for bone histomorphometry. Mean trabecular thickness is a measure of trabecular structure and is calculated as the reciprocal of total bone (trabecular) surfaces. Trabecular thickness is reduced by aging and osteoporosis. |
| Secondary | Bone Histomorphometry: Cortical Width | Month 24 and month 84 | Bone biopsy samples were prepared according to standard procedures for bone histomorphometry. Cortical width is the average width of both inner and outer cortices. |
| Secondary | Bone Histomorphometry: Cancellous Bone Volume by TRAP Histomorphometry | Month 24 and month 84 | Bone biopsy samples were prepared according to standard procedures for bone histomorphometry. Cancellous (trabecular) bone volume is the percent of the total marrow cavity that is occupied by cancellous bone (both mineralized and non-mineralized) measured by tartrate-resistant acid phosphatase (TRAP) staining histomorphometry. |
| Secondary | Bone Histomorphometry: Surface Density | Month 24 and month 84 | Bone biopsy samples were prepared according to standard procedures for bone histomorphometry. Surface density is calculated by total bone (trabecular) surfaces / total tissue volume. |
| Secondary | Bone Histomorphometry: Osteoblast - Osteoid Interface | Month 24 and month 84 | Bone biopsy samples were prepared according to standard procedures for bone histomorphometry. Osteoblast - osteoid interface is calculated as osteoblast surface / osteoid surface \* 100. |
| Secondary | Bone Histomorphometry: Osteoid Surface | Month 24 and month 84 | Bone biopsy samples were prepared according to standard procedures for bone histomorphometry. Osteoid surface is the percent of bone surface covered in osteoid. |
| Secondary | Bone Histomorphometry: Osteoid Thickness | Month 24 and month 84 | Bone biopsy samples were prepared according to standard procedures for bone histomorphometry. Osteoid thickness (width) is the mean thickness of osteoid seams on cancellous surfaces. Osteoid thickness is normally \<12.5 µm. Increased osteoid thickness suggests abnormal mineralization (osteomalacia). |
| Secondary | Bone Histomorphometry: Wall Thickness | Month 24 and month 84 | Bone biopsy samples were prepared according to standard procedures for bone histomorphometry. Wall thickness is the average thickness of trabecular bone structural units (BSU) and is used to assess the overall balance between resorption and formation. |
| Secondary | Bone Histomorphometry: Eroded Surface/Bone Surface | Month 24 and month 84 | Bone biopsy samples were prepared according to standard procedures for bone histomorphometry. Eroded surface/bone surface is the percentage of bone surface occupied by eroded (resorption) cavities (Howships lacunae), with or without osteoclasts. |
| Secondary | Bone Histomorphometry: Osteoclast Number - Length Based | Month 24 and month 84 | Bone biopsy samples were prepared according to standard procedures for bone histomorphometry. Osteoclast number was measured by quantitative histomorphometry and is expressed per mm of bone. |
| Secondary | Bone Histomorphometry: Osteoclast Number - Surface Based | Month 24 and month 84 | Bone biopsy samples were prepared according to standard procedures for bone histomorphometry. Osteoclast number was measured by quantitative histomorphometry and is expressed per 100 mm of bone surface area. |
| Secondary | Bone Histomorphometry: Osteoclast Number by TRAP - Length Based | Month 24 and month 84 | Bone biopsy samples were prepared according to standard procedures for bone histomorphometry. Osteoclast number was measured using TRAP staining and is expressed per mm of bone. |
| Secondary | Bone Histomorphometry: Osteoclast Number by TRAP - Surface Based | Month 24 and month 84 | Bone biopsy samples were prepared according to standard procedures for bone histomorphometry. Osteoclast number was measured using TRAP staining and is expressed per 100 mm of bone surface. Da |
| Secondary | Bone Histomorphometry: Single-label Surface | Month 24 and month 84 | Bone biopsy samples were prepared according to standard procedures for bone histomorphometry. A double tetracycline labeling procedure was used to allow visualization and quantification of sites of new bone formation. Tetracycline was given for two periods of 3 days separated by 14 days where no tetracycline was taken. A single label is deposited if formation either started or ended during the interval between the uses of the two courses of tetracycline administration. Single-label surface is expressed as a percentage of total bone surface. |
| Secondary | Bone Histomorphometry: Double-label Surface | Month 24 and month 84 | Bone biopsy samples were prepared according to standard procedures for bone histomorphometry. A double tetracycline labeling procedure was used to allow visualization and quantification of sites of new bone formation. Tetracycline was given for two periods of 3 days separated by 14 days where no tetracycline was taken. The presence of double labels indicates that normal bone mineralization was actively occurring over the entire labeling interval. Double-label surface is expressed as a percentage of total bone surface. |
| Secondary | Bone Histomorphometry: Mineralizing Surface | Month 24 and month 84 | Bone biopsy samples were prepared according to standard procedures for bone histomorphometry. A double tetracycline labeling procedure was used to allow visualization and quantification of sites of new bone formation. Tetracycline was given for two periods of 3 days separated by 14 days where no tetracycline was taken. Total mineralizing surfaces (MS) include all double and half of single-labeled surfaces. MS is expressed as a percentage of total bone surface. |
| Secondary | Bone Histomorphometry: Mineral Apposition Rate | Month 24 and month 84 | Bone biopsy samples were prepared according to standard procedures for bone histomorphometry. A double tetracycline labeling procedure was used to allow visualization and quantification of sites of new bone formation. Tetracycline was given for two periods of 3 days separated by 14 days where no tetracycline was taken. The mineral apposition rate (MAR) is the avarage rate at which new bone mineral is being added on any actively forming surface. MAR is calculated as the average distance between visible labels, divided by the labeling interval. |
| Secondary | Bone Histomorphometry: Adjusted Apposition Rate | Month 24 and month 84 | Bone biopsy samples were prepared according to standard procedures for bone histomorphometry. A double tetracycline labeling procedure was used to allow visualization and quantification of sites of new bone formation. Tetracycline was given for two periods of 3 days separated by 14 days where no tetracycline was taken. The mineral apposition rate (MAR) is the average rate at which new bone mineral is being added on any actively forming surface. Adjusted MAR is calculated as: (average distance between visible labels / labeling interval) \* (total mineralizing surface/total bone surface). |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT00523341/registered?page=2